Results 261 to 270 of about 776,387 (309)
Some of the next articles are maybe not open access.
Seminars in Respiratory and Critical Care Medicine, 2016
Small cell lung cancer (SCLC) is a high-grade neuroendocrine tumor characterized by rapid growth, early metastatic spread, and initial responsiveness to therapy. Although the incidence of SCLC is declining, it remains one of the common causes of cancer-related mortality. Initial evaluation of patients with SCLC should focus on determining the extent of
Erica B, Bernhardt, Shadia I, Jalal
openaire +4 more sources
Small cell lung cancer (SCLC) is a high-grade neuroendocrine tumor characterized by rapid growth, early metastatic spread, and initial responsiveness to therapy. Although the incidence of SCLC is declining, it remains one of the common causes of cancer-related mortality. Initial evaluation of patients with SCLC should focus on determining the extent of
Erica B, Bernhardt, Shadia I, Jalal
openaire +4 more sources
The Lancet, 2005
Small-cell lung carcinoma is an aggressive form of lung cancer that is strongly associated with cigarette smoking and has a tendency for early dissemination. Increasing evidence has implicated autocrine growth loops, proto-oncogenes, and tumour-suppressor genes in its development.
David M, Jackman, Bruce E, Johnson
openaire +2 more sources
Small-cell lung carcinoma is an aggressive form of lung cancer that is strongly associated with cigarette smoking and has a tendency for early dissemination. Increasing evidence has implicated autocrine growth loops, proto-oncogenes, and tumour-suppressor genes in its development.
David M, Jackman, Bruce E, Johnson
openaire +2 more sources
Mayo Clinic Proceedings, 2008
Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the cancer most commonly associated with various paraneoplastic syndromes, including the syndrome of inappropriate antidiuretic hormone secretion, paraneoplastic cerebellar degeneration, and Lambert-Eaton myasthenic syndrome.
Taimur, Sher, Grace K, Dy, Alex A, Adjei
openaire +2 more sources
Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the cancer most commonly associated with various paraneoplastic syndromes, including the syndrome of inappropriate antidiuretic hormone secretion, paraneoplastic cerebellar degeneration, and Lambert-Eaton myasthenic syndrome.
Taimur, Sher, Grace K, Dy, Alex A, Adjei
openaire +2 more sources
Chest Surgery Clinics of North America, 2001
The management of small-cell lung cancer (SCLC) evolved rapidly through the 1980s, but has stalled since then. The relative roles of surgery and radiotherapy in this former systemic disease have been worked out well. The chemotherapy of SCLC has progressed less rapidly.
G, Simon +2 more
openaire +2 more sources
The management of small-cell lung cancer (SCLC) evolved rapidly through the 1980s, but has stalled since then. The relative roles of surgery and radiotherapy in this former systemic disease have been worked out well. The chemotherapy of SCLC has progressed less rapidly.
G, Simon +2 more
openaire +2 more sources
Chest, 2003
Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain.
George R, Simon, Henry, Wagner
openaire +2 more sources
Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade. SCLC is staged as limited-stage disease and extensive-stage disease. Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain.
George R, Simon, Henry, Wagner
openaire +2 more sources
Amrubicin for non-small-cell lung cancer and small-cell lung cancer
Investigational New Drugs, 2007Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently, amrubicin was approved in Japan for the treatment of small- and non-small-cell lung cancers (SCLC and NSCLC). Here, we review the efficacy and toxicities of amrubicin monotherapy and amrubicin in combination with cisplatin for extensive ...
Takayasu, Kurata +3 more
openaire +2 more sources
The Lancet, 2011
In the decade since the last Lancet Seminar on lung cancer there have been advances in many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (NSCLC). An international panel of experts has been brought together to focus on changes in the epidemiology and pathological classification of NSCLC, the role of CT screening ...
Peter, Goldstraw +6 more
openaire +2 more sources
In the decade since the last Lancet Seminar on lung cancer there have been advances in many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (NSCLC). An international panel of experts has been brought together to focus on changes in the epidemiology and pathological classification of NSCLC, the role of CT screening ...
Peter, Goldstraw +6 more
openaire +2 more sources
Pathology of small-cell lung cancer
Journal of Cancer Research and Clinical Oncology, 2000The morphological differentiation between small-cell and non-small-cell lung cancer has great prognostic and therapeutic significance for the patient. Malignant lung tumors are now classified according to the new 1999 WHO/IASLC classification of lung and pleural tumors.
K, Junker, T, Wiethege, K M, Müller
openaire +2 more sources
History of Small-Cell Lung Cancer
Clinical Lung Cancer, 2011The history of small-cell lung cancer (SCLC) is one of the more fascinating stories of medicine, a story of hope and disappointment that characterizes it as 1 of the most elusive cancers. Its history can be divided into 3 intervals. The first interval encompassed the 30 years after the initial reports from Bernard in 1926 during which SCLC was ...
Shadi, Haddadin, Michael C, Perry
openaire +2 more sources
Treatment of small cell lung cancer
Critical Reviews in Oncology/Hematology, 2014Treatment of small cell lung cancer (SCLC) remains a significant challenge for the oncologists. Attempts to improve the results of first-line treatment have all failed so far and no real progress has been made in last years, emphasizing the need for novel strategies of treatment and the development of validated biomarkers. Patients with limited disease
Alessandro, Morabito +11 more
openaire +2 more sources